Utilizing artificial intelligence, Risklick’s Protocol AI accelerates clinical trial development, reduces costs, and enhances safety standards. Several established companies among them Debiopharm recognize the transformative capability of the solution.

利用人工智能，Risklick的协议AI加速了临床试验开发，降低了成本，并提高了安全标准。包括Debiopharm在内的几家知名公司认识到该解决方案的变革能力。

Developing new therapies typically requires an average of ten years and costs up to two billion dollars for companies. The most time-consuming and costly aspect of this process is the clinical trials, which are mandatory for validating new treatments before commercialization. These trials are complex, often resulting in significant delays or failures that impact both the cost and availability of new treatments for patients..

开发新疗法通常需要平均十年的时间，公司的成本高达20亿美元。这个过程中最耗时和最昂贵的方面是临床试验，这是在商业化之前验证新疗法的强制性要求。这些试验很复杂，通常会导致重大延误或失败，从而影响患者新疗法的成本和可用性。。

Clinical trials rely on complex protocols developed by experts, which describe all practical modalities of conducting the trial. Developing a protocol demands an average of 15 months of intensive work, where errors can have disastrous consequences.

临床试验依赖于专家开发的复杂方案，这些方案描述了进行试验的所有实际方式。制定协议平均需要15个月的密集工作，错误可能会产生灾难性后果。

To address these challenges, Risklick has developed Protocol AI, which reduces development time and costs by up to 35%. Protocol AI optimizes protocol development by leveraging data-driven insights from a comprehensive dataset of global historical trial data. This method not only reduces both time and costs but also ensures consistency across trials..

为了应对这些挑战，Risklick开发了协议AI，它将开发时间和成本降低了35%。协议AI通过利用来自全球历史试验数据综合数据集的数据驱动见解来优化协议开发。这种方法不仅减少了时间和成本，而且确保了试验的一致性。。

By using Protocol AI, experts can reduce protocol development time, make evidence-based decisions, and minimize the likelihood of amendments. The process involves three steps: exploring historical trial data, selecting key parameters based on evidence, and efficiently developing tailored protocols with generative AI.

通过使用协议AI，专家可以减少协议开发时间，做出基于证据的决策，并最大限度地减少修改的可能性。该过程包括三个步骤：探索历史试验数据，根据证据选择关键参数，以及使用生成性AI有效开发定制协议。

This approach accelerates innovation and the delivery of new treatments to patients, paving the way for medical advancement..

这种方法加速了创新，并为患者提供了新的治疗方法，为医学进步铺平了道路。。

Risklick has partnered with leading biotechnology and medical device companies, including Debiopharm and ISS AG. Debiopharm has invested in the Bern-based startup via its Innovation Fund. “This investment in Risklick is part of our strategy to equip our collaborators in the R&D, Clinical Operations, Regulatory Affairs departments with a collaborative tool designed to enhance their workflows, facilitate trial design and support regulatory compliance.

Risklick与领先的生物技术和医疗器械公司合作，包括Debiopharm和ISS AG。Debiopharm通过其创新基金投资了这家位于伯尔尼的初创公司。“对Risklick的投资是我们战略的一部分，我们的战略是为研发、临床运营、监管事务部门的合作者提供一种合作工具，旨在增强他们的工作流程，促进试验设计并支持法规遵从性。

We are committed to addressing internal pain points by introducing or supporting through innovative solutions”, explains Cedric Odje, Investment Associate at Debiopharm Innovation Fund..

Debiopharm创新基金的投资助理Cedric Odje解释说：“我们致力于通过引入或支持创新解决方案来解决内部难点。”

Dr. Poorya Amini CEO and co-founder of Risklick, adds: “We are on a mission to revolutionize clinical trial protocol development with our disruptive approach and technology.  Our vision is to become the standard in clinical trial protocol development, making trials faster, cheaper and safer for the benefit of all.”.

Risklick首席执行官兼联合创始人Poorya Amini博士补充道：“我们的使命是用我们的颠覆性方法和技术彻底改变临床试验方案的开发。我们的愿景是成为临床试验方案开发的标准，使试验更快，更便宜，更安全，造福于所有人。”